Cooke L D, Cooke T G, Bootz F, Forster G, Helliwell T R, Spiller D, Stell P M
Department of Otorhinolaryngology, University of Liverpool, UK.
Br J Cancer. 1990 May;61(5):759-62. doi: 10.1038/bjc.1990.169.
We measured tumour cellular DNA in 102 patients entered into two phase III trials of chemotherapy for end stage squamous carcinoma of the head and neck. The median survival of untreated patients with aneuploid tumours was 55 days compared with 224 days for patients treated with cisplatinum. This difference was highly significant. In contrast the median survival of untreated patients with diploid tumours was 74 days compared with 118 days for treated patients. Although this difference is statistically significant, the increased survival of 6 weeks is of no clinical benefit compared with the prolongation of survival of 6 months in patients with aneuploid tumours. Multivariate analysis showed that the significant predictors of survival were Karnofsky status, response to chemotherapy and ploidy.
我们对102例进入两项晚期头颈部鳞状细胞癌化疗III期试验的患者的肿瘤细胞DNA进行了检测。非整倍体肿瘤的未治疗患者的中位生存期为55天，而接受顺铂治疗的患者为224天。这种差异具有高度显著性。相比之下，二倍体肿瘤的未治疗患者的中位生存期为74天，接受治疗的患者为118天。虽然这种差异具有统计学意义，但与非整倍体肿瘤患者生存期延长6个月相比，二倍体肿瘤患者生存期仅延长6周并无临床益处。多变量分析表明，生存的显著预测因素为卡诺夫斯基状态、化疗反应和倍性。
